When Should Advanced Therapy Be Started in Crohn’s Disease?

Answer in brief: Advanced therapy should be considered early in moderate-to-severe Crohn’s disease and in patients with features that predict progression or complications. Modern guidance has moved away from requiring prolonged failure of lower-efficacy agents before biologic or small-molecule treatment. The goal is durable steroid-free control of inflammation before irreversible bowel damage develops.

The old step-up model has weakened

Crohn’s disease can cause cumulative transmural damage even when symptoms are intermittent. Repeated corticosteroid courses or prolonged use of weakly effective therapies may control symptoms temporarily while strictures, fistulas or nutritional consequences evolve. Current ACG and AGA guidance therefore supports earlier use of effective advanced therapies in appropriately selected moderate-to-severe disease.

Identify patients who should not wait

Features favouring early advanced therapy include extensive disease, deep ulceration, significant inflammatory burden, perianal or penetrating disease, stricturing phenotype, upper-GI involvement, repeated steroid need, hospitalization, young age at diagnosis, substantial weight loss or anemia, and failure to normalize objective markers.

Choose therapy by efficacy, phenotype and safety

Treatment selection is individualized. Anti-TNF agents remain especially important for fistulizing disease; ustekinumab, IL-23 pathway agents and vedolizumab provide alternative mechanisms; upadacitinib is an oral option for selected patients. Prior biologic exposure, comorbidities, infection risk, malignancy history, pregnancy plans, speed of onset and patient preferences all matter.

Do not confuse symptoms with inflammatory activity

Before escalating therapy, confirm that symptoms reflect active Crohn’s disease rather than fibrostenosis, bile-acid diarrhea, infection, IBS overlap, SIBO or another process. Biomarkers, cross-sectional imaging and endoscopy are used strategically to establish the inflammatory target.

Advanced therapy is part of a treat-to-target plan

Starting a biologic is not the endpoint. Reassess response using symptoms plus objective inflammation measures and modify therapy if the chosen target is not achieved.

What trainees should remember

Start effective therapy before damage accumulates. Moderate-to-severe or prognostically high-risk Crohn’s disease should not be forced through a long sequence of low-efficacy treatments simply to satisfy an outdated step-up model.

Frequently asked questions

Does every newly diagnosed Crohn’s patient need a biologic?

No. Mild, limited, low-risk disease may be managed differently. The decision is based on severity, location, phenotype, prognosis and patient factors.

Are corticosteroids an alternative to advanced maintenance therapy?

No. Corticosteroids are induction/rescue tools, not maintenance therapy.

References and further reading

1. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Lichtenstein GR, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2025.

4. Scott FI, et al. AGA Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Crohn's Disease. Gastroenterology. 2025.